These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11349696)

  • 1. Short-term cardiovascular effects of methylphenidate and adderall.
    Findling RL; Short EJ; Manos MJ
    J Am Acad Child Adolesc Psychiatry; 2001 May; 40(5):525-9. PubMed ID: 11349696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developmental aspects of psychostimulant treatment in children and adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; Short EJ; Manos MJ
    J Am Acad Child Adolesc Psychiatry; 2001 Dec; 40(12):1441-7. PubMed ID: 11765290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children.
    Findling RL; Biederman J; Wilens TE; Spencer TJ; McGough JJ; Lopez FA; Tulloch SJ;
    J Pediatr; 2005 Sep; 147(3):348-54. PubMed ID: 16182674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.
    Hammerness P; Wilens T; Mick E; Spencer T; Doyle R; McCreary M; Becker J; Biederman J
    J Pediatr; 2009 Jul; 155(1):84-9, 89.e1. PubMed ID: 19394037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Biederman J; Mick E; Surman C; Doyle R; Hammerness P; Harpold T; Dunkel S; Dougherty M; Aleardi M; Spencer T
    Biol Psychiatry; 2006 May; 59(9):829-35. PubMed ID: 16373066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network
    Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study.
    Wilens TE; Biederman J; Lerner M;
    J Clin Psychopharmacol; 2004 Feb; 24(1):36-41. PubMed ID: 14709945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective study of stimulant response in preschool children: insights from ROC analyses.
    Short EJ; Manos MJ; Findling RL; Schubel EA
    J Am Acad Child Adolesc Psychiatry; 2004 Mar; 43(3):251-9. PubMed ID: 15076257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication.
    Schertz M; Adesman AR; Alfieri NE; Bienkowski RS
    Pediatrics; 1996 Oct; 98(4 Pt 1):763-9. PubMed ID: 8885958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 24-hour ambulatory blood pressure monitoring in male children receiving stimulant therapy.
    Stowe CD; Gardner SF; Gist CC; Schulz EG; Wells TG
    Ann Pharmacother; 2002; 36(7-8):1142-9. PubMed ID: 12086544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A; Richard C; Prinzo R; Binder C
    Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder.
    Pliszka SR; Browne RG; Olvera RL; Wynne SK
    J Am Acad Child Adolesc Psychiatry; 2000 May; 39(5):619-26. PubMed ID: 10802980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting.
    Swanson J; Wigal S; Greenhill L; Browne R; Waslick B; Lerner M; Williams L; Flynn D; Agler D; Crowley KL; Fineberg E; Regino R; Baren M; Cantwell D
    Psychopharmacol Bull; 1998; 34(1):55-60. PubMed ID: 9564199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder.
    Pelham WE; Gnagy EM; Chronis AM; Burrows-MacLean L; Fabiano GA; Onyango AN; Meichenbaum DL; Williams A; Aronoff HR; Steiner RL
    Pediatrics; 1999 Dec; 104(6):1300-11. PubMed ID: 10585981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effectiveness of methylphenidate and Adderall in school-age youths with attention-deficit/hyperactivity disorder.
    Manos MJ; Short EJ; Findling RL
    J Am Acad Child Adolesc Psychiatry; 1999 Jul; 38(7):813-9. PubMed ID: 10405498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder.
    Pelham WE; Aronoff HR; Midlam JK; Shapiro CJ; Gnagy EM; Chronis AM; Onyango AN; Forehand G; Nguyen A; Waxmonsky J
    Pediatrics; 1999 Apr; 103(4):e43. PubMed ID: 10103335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.
    Sonuga-Barke EJ; Swanson JM; Coghill D; DeCory HH; Hatch SJ
    BMC Psychiatry; 2004 Sep; 4():28. PubMed ID: 15458569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.